Document Classification

Section Type: RESULTS

Text: The cumulative incidences of moderate to severe abdominal pain, dyspepsia, or nausea (composite endpoint) were : naproxen 500 mg (12. 0 % ; 95 % CI 9. 9 % -14. 0 %), celecoxib 50 mg bid (7. 1 % ; 95 % CI 5. 0 % -9. 2 %), celecoxib 100 mg bid (7. 8 % ; 95 % CI 6. 0 % -9. 5 %), celecoxib 200 mg bid (8. 1 % ; 95 % CI 6. 4 % -9. 9 %), celecoxib 400 mg bid (6. 0 % ; 95 % CI 3. 6 % -8. 4 %), and placebo (8. 5 % ; 95 % CI 6. 5 % -10. 8 %).